Celgene-sponsored Trials

The clinical trials listed on Celgene.com are Celgene-sponsored trials that are actively recruiting patients. After searching by disease, a list of available Celgene-sponsored trials will be displayed. Each listed trial contains a hyperlink to a website called ClinicalTrials.gov. On this website, you will find additional information about the study such as a study description, entry criteria, contact information and facility names where the study is being conducted.

Click here to Learn More >



Study ID Title
NCT03575351 A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
NCT03554993 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects
NCT03539419 Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain
NCT03521180 A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease
NCT03486067 Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03484702 Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
NCT03467958 An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
NCT03464097 A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
NCT03440385 Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440372 Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03435796 Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
NCT03435341 Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain
NCT03374085 A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03363815 A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects
NCT03361748 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)
NCT03342404 A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
NCT03337022 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis
NCT03324503 A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
NCT03310619 A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
NCT03290443 A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
NCT03288974 Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
NCT03284879 Post-Marketing Surveillance Study of OTEZLA
NCT03283202 Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors
NCT03257631 A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
NCT03220347 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
NCT03194542 A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
NCT03161483 A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus
NCT03142191 A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
NCT03106324 A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
NCT03098589 Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
NCT03097003 A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium
NCT03096990 A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium
NCT03001804 Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
NCT02954081 APremilast After FumaRic Acid Ester Treatment
NCT02946333 A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain
NCT02903069 Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
NCT02902900 An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice
NCT02875223 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
NCT02875184 A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
NCT02859324 A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
NCT02848001 A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
NCT02773030 A Safety Study to Determine Dose and Tolerability of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
NCT02740218 A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
NCT02692339 Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
NCT02677922 A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02658929 Study of bb2121 in Multiple Myeloma
NCT02652494 Observational Study of Apremilast in Patients With Psoriasis in The Netherlands
NCT02641002 A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
NCT02635061 Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
NCT02577406 An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
NCT02555839 Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
NCT02555813 Treatment of Pancreatic Cancer With Abraxane
NCT02551185 ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
NCT02531126 Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
NCT02494258 A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.
NCT02450877 A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
NCT02435992 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
NCT02417285 A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
NCT02406742 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02367196 A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
NCT02279654 Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
NCT02164955 A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
NCT02031419 Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT01996865 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01688011 Connect® MDS/AML Disease Registry
No Results